Pharmaceuticals

Roche

Yilian Bio's YL201 Achieves Positive Phase III Results in Nasopharyngeal Cancer, Secures $570M Deal with Roche

Nurix Therapeutics and Roche Partner Globally to Develop Bexobrutideg

Roche Granted FDA Priority Review for Giredestrant in Early Breast Cancer

Roche's Obinutuzumab Injection Proposed for Priority Review for Primary Membranous Nephropathy Treatment

Roche rapidly develops a PCR test for Ebola within six days

PharmaMar Announces EMA Approval of Zepzelca Combination for Extensive-Stage SCLC Maintenance

FDA Approves FoundationOne CDx for Genentech's Itovebi to Treat HR+/HER2- Breast Cancer

FDA Accepts Roche's NDA for Giredestrant and Grants Priority Review for Breast Cancer Treatment

Genentech to Present Clinical Data for Obesity Drugs Enicepatide and Petrelintide at ADA 2026, Roche Shares Rise 1.82%

Roche Launches LiverPRO Liver Disease Detection Panel to Enhance Clinical Decision Making

Genentech to Present New Data on Giredestrant's Potential in Early Breast Cancer Treatment at ASCO 2026

MPP and Roche Sign Voluntary License Agreement for Baloxavir Marboxil

Roche Signs Agreement with MPP to License Xofluza Generics in 129 Countries

AstraZeneca and Roche Diagnostics APAC Partner to Develop Advanced Pathology Solutions for Breast and Lung Cancer

FDA Approves Genentech's Tecentriq for ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer

Roche Launches New Blood Test for Alzheimer's Pathology with CE Certification

Roche Signs Final Acquisition Agreement for PathAI

Roche to Present Comprehensive Ophthalmology Data Package at ARVO Annual Meeting

Roche Subsidiary Genentech to Release New Efficacy Data for Vabysmo

Roche Holding AG (OTCMKTS:RHHBY) Short Interest Significantly Decreased

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

NRIX

RHHBY

Roche and Nurix Therapeutics signed a $2.3 billion collaboration to co-develop and commercialize bexobrutideg, an investigational BTK degrader. The deal includes a $700 million upfront payment, with potential milestones reaching the total value. Development costs are split 60/40 between Roche and Nurix, respectively. Profits in the U.S. are shared equally, while Roche leads international commercialization with royalties for Nurix. The transaction is expected to close in Q3 2026.

rttnews

Nurix Therapeutics

ROCHE HOLDINGS AG

Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg

Roche and Nurix Therapeutics have entered an exclusive collaboration to co-develop and commercialize bexobrutideg, a novel BTK degrader. Nurix will receive over $700 million upfront plus milestones. The deal aims to address resistance in blood cancers like CLL and explore immunology/neurology applications. Phase III trials for second-line CLL are planned for summer 2026, with the transaction closing pending antitrust clearance.

Pharmexec

<![CDATA[Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg ]]>

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics

Roche(RHHBY.US)

Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg

<![CDATA[Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg ]]>

Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics